FDA
-
-
-
-
-
-
-
Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
-
-
-
-
-
-
-
AACR 2024 Annual Meeting-Visit Senhwa Biosciences Exhibit Booth
-
-
-
-
-
-
-
At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma
-
-
-
-
-
-
-
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference
-
-
-
-
-
-
-
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data
-
-
-
-
-
-
-
Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment
-
-
-
-
-
-
329,074 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

